CHEK
Price
$1.19
Change
+$0.05 (+4.39%)
Updated
Nov 5, 10:40 AM (EDT)
Earnings call today
XWEL
Price
$1.72
Change
-$0.03 (-1.71%)
Updated
Nov 5, 11:48 AM (EDT)
Ad is loading...

CHEK vs XWEL

Header iconCHEK vs XWEL Comparison
Open Charts CHEK vs XWELBanner chart's image
Check-Cap
Price$1.19
Change+$0.05 (+4.39%)
Volume$100
CapitalizationN/A
XWELL
Price$1.72
Change-$0.03 (-1.71%)
Volume$1.32K
CapitalizationN/A
View a ticker or compare two or three
CHEK vs XWEL Comparison Chart
Loading...
CHEK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
XWEL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
CHEK vs. XWEL commentary
Nov 05, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHEK is a Hold and XWEL is a Hold.

COMPARISON
Comparison
Nov 05, 2024
Stock price -- (CHEK: $1.14 vs. XWEL: $1.75)
Brand notoriety: CHEK and XWEL are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CHEK: 78% vs. XWEL: 15%
Market capitalization -- CHEK: $18.19M vs. XWEL: $7.06M
CHEK [@Medical Specialties] is valued at $18.19M. XWEL’s [@Medical Specialties] market capitalization is $7.06M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.97B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHEK’s FA Score shows that 1 FA rating(s) are green whileXWEL’s FA Score has 1 green FA rating(s).

  • CHEK’s FA Score: 1 green, 4 red.
  • XWEL’s FA Score: 1 green, 4 red.
According to our system of comparison, XWEL is a better buy in the long-term than CHEK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHEK’s TA Score shows that 4 TA indicator(s) are bullish while XWEL’s TA Score has 2 bullish TA indicator(s).

  • CHEK’s TA Score: 4 bullish, 4 bearish.
  • XWEL’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, CHEK is a better buy in the short-term than XWEL.

Price Growth

CHEK (@Medical Specialties) experienced а -3.39% price change this week, while XWEL (@Medical Specialties) price change was -3.58% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.55%. For the same industry, the average monthly price growth was -0.26%, and the average quarterly price growth was -1.49%.

Reported Earning Dates

CHEK is expected to report earnings on Feb 26, 2025.

XWEL is expected to report earnings on Nov 15, 2023.

Industries' Descriptions

@Medical Specialties (+0.55% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CHEK($18.2M) has a higher market cap than XWEL($7.06M). XWEL YTD gains are higher at: 0.299 vs. CHEK (-45.192). XWEL has higher annual earnings (EBITDA): -17.82M vs. CHEK (-18.8M). CHEK has more cash in the bank: 32.1M vs. XWEL (26.1M). CHEK has less debt than XWEL: CHEK (83K) vs XWEL (11.5M). XWEL has higher revenues than CHEK: XWEL (30.3M) vs CHEK (0).
CHEKXWELCHEK / XWEL
Capitalization18.2M7.06M258%
EBITDA-18.8M-17.82M106%
Gain YTD-45.1920.299-15,122%
P/E RatioN/AN/A-
Revenue030.3M-
Total Cash32.1M26.1M123%
Total Debt83K11.5M1%
FUNDAMENTALS RATINGS
CHEK vs XWEL: Fundamental Ratings
CHEK
XWEL
OUTLOOK RATING
1..100
569
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
62
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
9358
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CHEK's Valuation (26) in the Medical Specialties industry is somewhat better than the same rating for XWEL (62) in the Other Consumer Services industry. This means that CHEK’s stock grew somewhat faster than XWEL’s over the last 12 months.

CHEK's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as XWEL (100) in the Other Consumer Services industry. This means that CHEK’s stock grew similarly to XWEL’s over the last 12 months.

CHEK's SMR Rating (97) in the Medical Specialties industry is in the same range as XWEL (98) in the Other Consumer Services industry. This means that CHEK’s stock grew similarly to XWEL’s over the last 12 months.

XWEL's Price Growth Rating (58) in the Other Consumer Services industry is somewhat better than the same rating for CHEK (93) in the Medical Specialties industry. This means that XWEL’s stock grew somewhat faster than CHEK’s over the last 12 months.

XWEL's P/E Growth Rating (1) in the Other Consumer Services industry is significantly better than the same rating for CHEK (100) in the Medical Specialties industry. This means that XWEL’s stock grew significantly faster than CHEK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CHEKXWEL
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 8 days ago
77%
Bullish Trend 26 days ago
78%
Declines
ODDS (%)
Bearish Trend 6 days ago
89%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
View a ticker or compare two or three
Ad is loading...
CHEK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
XWEL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PYCR15.720.24
+1.55%
Paycor HCM
LYRA0.26N/A
+1.54%
Lyra Therapeutics
WLK131.48-0.66
-0.50%
Westlake Corp
COFS32.51-0.47
-1.43%
ChoiceOne Financial Services
TWI6.45-0.34
-5.01%
Titan International

CHEK and

Correlation & Price change

A.I.dvisor tells us that CHEK and TWST have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CHEK and TWST's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHEK
1D Price
Change %
CHEK100%
-0.87%
TWST - CHEK
26%
Poorly correlated
+1.11%
RSLS - CHEK
26%
Poorly correlated
+2.89%
ICAD - CHEK
26%
Poorly correlated
-4.67%
WRBY - CHEK
25%
Poorly correlated
+0.69%
SENS - CHEK
25%
Poorly correlated
-0.77%
More

XWEL and

Correlation & Price change

A.I.dvisor tells us that XWEL and DRIO have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XWEL and DRIO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XWEL
1D Price
Change %
XWEL100%
+1.36%
DRIO - XWEL
28%
Poorly correlated
-3.69%
COCH - XWEL
25%
Poorly correlated
-7.84%
XRAY - XWEL
23%
Poorly correlated
-0.72%
NVCR - XWEL
22%
Poorly correlated
+2.47%
CHEK - XWEL
21%
Poorly correlated
-0.87%
More